Nioboxidfluoride mit Blockstrukturen — Elektronenmikroskopische Durchstrahlungsaufnahmen und ihre Simulation

Niobiumoxidefluorides Nb₅₉O₁₄₇F, Nb₃₁O₇₇F, Nb₆₅O₁₆₁F₃ and Nb₃₄O₈₄F₂ were prepared by reaction of Nb₂O₅ and Nb₃O₇F at 1 270°C. These niobiumoxidefluorides have blockstructures which were examined by high resolution electron microscopy. The observed images of the crystal structures were compared with computer simulated images.

     

Assignment of E/Z isomers in Schiff bases of 3-acyltetramic acids with ethylenediamine by 1H and 13C NMR spectroscopy

The reaction of ethylenediamine with an equivalent mixture of diversely substituted 3-acyltetramic acids leads to Z/Z, Z/E, E/Z and E/E isomers. The E/Z isomerisation is slow in the NMR time scale of the ¹H and ¹³C chemical shifts; therefore at room temperature and in deuterochloroform all isomers of the new synthesized asymmetric compounds N,N′-ethylene-(1-ethyl-5,5-dimethyl-1′,5′,5′-trimethyl-3,3′-acetyltetramic acid) a, N,N′-ethylene-(5,5-dimethyl-1′,5′,5′-trimethyl-3,3′-acetyltetramic acid) b and, N,N′-ethylene-(1,5,5-trimethyl-1′,5′,5′-trimethyl-3-acetyl-3′-formyl-tetramic acid) c could be found in the corresponding spectra. To assign the ¹³C NMR signals we used two-dimensional ¹³C-¹H one-bond (HMQC) and ¹³C-¹H multibond (HMBC) correlated spectroscopy and the empirical rule that CO signals involved in hydrogen bonds are shifted to a lower field. The relative stability of isomers depending on substitution pattern could be estimated from the composition of the equilibria. b crystallizes as Z/Z isomer from ethanolic solution. The X-ray structural analysis of b has shown two CH-O hydrogen bonds. Received: 31 May 1996 / Revised: 26 June 1996 / Accepted: 1 July 1996     

Unusual peak defocusing in capillary GC on hexakis(2,6-diO-pentyl-3-O-acetyl)-α-cyclodextrin stationary phase

An unusual peak defocusing effect influencing chromatographic performance over a limited range of elution temperatures is described for hexakis(2,6-di-O-pentyl-3-O-acetyl)-α-cyclodextrin stationary phase. Since this phenomenon is likely to be dependent on minor details of the cyclodextrin molecule, full assignment of the ¹H- and ¹³C-NMR-spectra are given.     

Stereoisomeric flavor compounds,part LVIII: The use of heptakis(2,3-di-O-methyl-6-O-tert-butyldimethylsilyl)-β-cyclodextrin as a chiral stationary phase in flavor analysis

The characteristics of the new chiral stationary phase heptakis(2,3-di-O-methyl-6-O-tert-butyldimethylsilyl)-β-cyclodextrin are outlined and compared with permethyl- and perethyl-β-cyclodextrins.     

A new family of mixed-valence dinuclear rhodium complexes containing the two metal centers in different stereochemical environments

A series of dinuclear chelate complexes of the general composition [Rh2(kappa2-L)2(mu-CR2)2(mu-SbiPr3)] (R = Ph, p-Tol; L = CF3CO2-, acac-, acac-f3-) and [Rh2Cl(kappa2-L)(mu-CR2)2(mu-SbiPr3)] (R = Ph, p-Tol; L = acac-, acac-f3-) has been prepared by replacement of the chloro ligands in the precursors [Rh2Cl2(mu-CR2)2(mu-SbiPr3)] by anionic chelates. The lability of the SbiPr3 bridge in the rhodium dimers is illustrated by the reactions of [Rh2(kappa2-acac)2(mu-CR2)2(mu-SbiPr3)] (7, 8) with Lewis bases such as CO, CNtBu, and SbEt3 which lead to the formation of the substitution products [Rh2(kappa2-acac)2(mu-CR2)2(mu-L')] (13-16) in excellent yields. Treatment of 7 and 8 with sterically demanding tertiary phosphanes PR3 (R3 = iPr3, iPr2Ph, iPrPh2, Ph3) affords the mixed-valence Rh0-RhII complexes [(kappa2-acac)2Rh(mu-CPh2)2Rh(PR3)] (21-24) and [(kappa2-acac)2Rh(mu-C(p-Tol)2]2Rh(PiPr3)] (25) for which there is no precedence. The terminal PiPr3 ligand of 21 is easily displaced by alkynes, CNtBu, and CO to give, by preserving the [(kappa2-acac)2Rh(mu-CPh2)2Rh] molecular core, the related dinuclear compounds 26-31 in which the coordination number of the Rh0 center is 3, 4, or 5. The molecular structures of [Rh2Cl(kappa2-acac)(mu-CPh2)2(mu-SbiPr3)] (5), [Rh2(kappa2-acac)2(mu-CPh2)2(mu-CO)] (13), [(kappa2-acac)2Rh(mu-CPh2)2Rh(PiPr3)] (21), and [(kappa2-acac)2Rh(mu-CPh2)2Rh(CNtBu)2] (30) have been determined crystallographically.     

Synthese und Charakterisierung neuer intramolekular stickstoffstabilisierter Organoaluminium‐ und Organogalliumalkoxide

Synthesis and Characterization of New Intramolecularly Nitrogen‐stabilized Organoaluminium‐ and Organogallium Alkoxides The intramolecularly nitrogen stabilized organoaluminium alkoxides [Me₂Al{μ‐O(CH₂)₃NMe₂}]₂ ( 1a ), Me₂AlOC₆H₂(CH₂NMe₂)₃‐2,4,6 ( 2a ), [(S)‐Me₂Al{μ‐OCH₂CH(i‐Pr)NH‐i‐Pr}]₂ ( 3a ) and [(S)‐Me₂Al{μ‐OCH₂CH(i‐Pr)NHCH₂Ph}]₂ ( 4 ) are formed by reacting equimolar amounts of AlMe₃ and Me₂N(CH₂)₃OH, C₆H₂[(CH₂NMe₂)₃‐2,4,6]OH, (S)‐i‐PrNHCH(i‐Pr)CH₂OH, or (S)‐PhCH₂NHCH(i‐Pr)CH₂OH, respectively. An excess of AlMe₃ reacts with Me₂N(CH₂)₂OH, Me₂N(CH₂)₃OH, C₆H₂[(CH₂NMe₂)₃‐2,4,6]OH, and (S)‐i‐PrNHCH(i‐Pr)CH₂OH producing the “pick‐a‐back” complexes [Me₂AlO(CH₂)₂NMe₂](AlMe₃) ( 5 ), [Me₂AlO(CH₂)₃NMe₂](AlMe₃) ( 1b ), [Me₂AlOC₆H₂(CH₂NMe₂)₃‐2,4,6](AlMe₃)₂ ( 2b ), and [(S)‐Me₂AlOCH₂CH(i‐Pr)NH‐i‐Pr](AlMe₃) ( 3b ), respectively. The mixed alkyl‐ or alkenylchloroaluminium alkoxides [Me(Cl)Al{μ‐O(CH₂)₂NMe₂}]₂ ( 6 ) and [{CH₂=C(CH₃)}(Cl)Al{μ‐O(CH₂)₂NMe₂}]₂ ( 8 ) are to obtain from Me₂AlCl and Me₂N(CH₂)₂OH and from [Cl₂Al{μ‐O(CH₂)₂NMe₂}]₂ ( 7 ) and CH₂=C(CH₃)MgBr, respectively. The analogous dimethylgallium alkoxides [Me₂Ga{μ‐O(CH₂)₃NMe₂}]₂ ( 9 ), [(S)‐Me₂Ga{μ‐OCH₂CH(i‐Pr)NH‐i‐Pr}]_n ( 10 ), [(S)‐Me₂Ga{μ‐OCH₂CH(i‐Pr)NHCH₂Ph}]_n ( 11 ), [(S)‐Me₂Ga{μ‐OCH₂CH(i‐Pr)N(Me)CH₂Ph}]_n ( 12 ) and [(S)‐Me₂Ga{μ‐OCH₂(C₄H₇NHCH₂Ph)}]_n ( 13 ) result from the equimolar reactions of GaMe₃ with the corresponding alcohols. The new compounds were characterized by elemental analyses, ¹H‐, ¹³C‐ and ²⁷Al‐NMR spectroscopy, and mass spectrometry. Additionally, the structures of 1a , 1b , 2a , 2b , 3a , 5 , 6 and 8 were determined by single crystal X‐ray diffraction.     

Identification and quantification of the antipsychotics risperidone,aripiprazole, pipamperone and their major metabolites in plasma using ultra‐high performance liquid chromatography–mass spectrometry

The antipsychotics risperidone, aripiprazole and pipamperone are frequently prescribed for the treatment in children with autism. The aim of this study was to validate an ultra‐high performance liquid chromatography–mass spectrometry method for the quantification of these antipsychotics in plasma. An ultra‐high performance liquid chromatography–mass spectrometry assay was developed for the determination of the drugs and metabolites. Gradient elution was performed on a reversed‐phase column with a mobile phase consisting of ammonium acetate, formic acid in methanol or in Milli‐Q ultrapure water at a flow rate of 0.5 mL/min. The method was validated according to the US Food and Drug Administration guidelines. The analytes were found to be stable enough after reconstitution and injection of only 5 μL improved the accuracy and precision in combination with the internal standard. Calibration curves of all five analytes were linear. All analytes were stable for at least 72 h in the autosampler and the high quality control of 9‐OH‐risperidone was stable for 48 h. The method allows quantification of all analytes. The advantage of this method is the combination of a minimal injection volume, a short run‐time, an easy sample preparation method and the ability to quantify all analytes in one run. Copyright © 2015 John Wiley & Sons, Ltd.     

Quantitative NMR (qNMR) for pharmaceutical analysis: The pioneering work of George Hanna at the US FDA

In the last two decades, quantitative NMR (qNMR) has become increasingly important for the analysis of pharmaceuticals, chemicals, and natural products including dietary supplements. For the purpose of quality control and chemical standardization of a large variety of pharmaceutical, chemical, and medicinal products, qNMR has proven to be a valuable orthogonal quantification method and a compelling alternative to chromatographic techniques. This work reviews a fundamental component of the early development of qNMR, reflected in the pioneering work of the late George M. Hanna during the years between 1984 and 2006 at the US Food and Drug Administration (FDA). Because Hanna performed the majority of his groundbreaking work on a 90‐MHz instrument, his legacy output connects with recent progress in low‐field benchtop NMR instrumentation. Hanna gradually established the utility of qNMR for the routine quality control analyses practiced in pharmaceutical and related operations well ahead of his peers. His work has the potential to inspire new developments in qNMR applied to small molecules of biomedical importance.